ABTECT - Maintenance
← catalyst calendarSponsored by Abivax S.A. (industry) · ABVX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
1,116actual
Sites
413
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-04-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: ABX464 — also filed as Obefazimod
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFRate of subjects in clinical remission at Week 44
measured Week 44
Number and percentage of all treatment-emergent adverse events (TEAEs)
measured Week 44
Number and percentage of all serious adverse events (SAEs)
measured Week 44
Number and percentage of all causally related TEAEs/SAEs
measured Week 44
Permalink · ABVX's whole pipeline · Catalyst calendar · Every registered study · What changed